A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma

Inclusion Criteria: * Histologically confirmed adrenocortical carcinoma that is locally advanced or metastatic and not amenable to surgical resection. * Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1). * Eastern Cooperative Oncology Group (ECOG) performance status (PS) \<= 2 * Predicted life expectancy \>= 12 weeks. * At least 1 but no more than 2 prior drug regimens (including molecular targeted therapy, systemic cytotoxic chemotherapy, biologics, and/or vaccines) for locally advanced/metastatic ACC. * A minimum of 3 weeks must have elapsed between the end of prior treatment and randomization. * All patients must have received prior mitotane, either as neoadjuvant, adjuvant, or locally advanced/metastatic therapy. * Adjuvant and neoadjuvant mitotane therapy will not be counted as prior drug regimens or as systemic cytotoxic chemotherapy. * Prior radiation therapy is permitted provided patients have recovered from the acute, toxic effects of radiotherapy prior to randomization. * A minimum of 21 days must have elapsed between the end of radiotherapy and randomization. * Prior surgery is permitted provided that adequate wound healing has occurred prior to randomization. * Fasting glucose \< = 150 mg/dL (8.3 mmol/L). * Adequate hematopoietic, hepatic, and renal function defined as follows: Neutrophil count \>= 1.5 x 10\^9 /L; * Platelet count \>= 100 x 10\^9 /L; * Bilirubin \<= 1.5 x Upper Limit of Normal (ULN); * AST and ALT…